# OnCo record solstice-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/solstice-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "solstice-oncology" ;
  schema:name "Solstice Oncology"@en ;
  schema:alternateName "Solstice Oncology, Inc."@en ;
  schema:description "Solstice Oncology is testing porustobart, an antibody that releases a brake on the immune system, given with the immunotherapy pembrolizumab before surgery. Its first trial is in people with stage II to III colon cancer of the common type that has not usually responded to immunotherapy (microsatellite stable)."@en ;
  schema:url <https://onco.cc/companies/solstice-oncology/>, <https://solsticeoncology.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://solsticeoncology.com/>, <https://solsticeoncology.com/press-release>, <https://clinicaltrials.gov/study/NCT07808151> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/colon-cancer/> ;
  onco:sections <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:targets <https://onco.cc/targets/ctla4/>, <https://onco.cc/targets/pd1/> ;
  onco:trials <https://onco.cc/trials/nct07808151/> .